Watch for Patients on the Parkinson’s Med Nourianz

Istradefylline (Nourianz, NUR-ee-anz) will be the first NON-dopaminergic “adenosine antagonist” for Parkinson’s disease...

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote